Benzinga | Mar 11, 2021 11:25AM EST

Credit Suisse Maintains Outperform on Ascendis Pharma, Lowers Price Target to $176

Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $178 to $176.